David V. Sheehan, MD, MBA
Professor of Psychiatry
Director, Office of Psychiatry Research
University of South Florida Institute for Research in Psychiatry
Depression frequently presents with other psychosocial comorbidities such as generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, social anxiety disorder, or post-traumatic stress disorder. Recognizing the comorbidities and understanding their integral relationship with depression represents a challenge for primary care physicians and other healthcare providers. There are several therapeutic approaches, including monotherapy and combination therapy. Many of these conditions are treatable and their comorbidity offers therapeutic opportunities because some of the same medications used to treat depression are effective in treating these other disorders.
. Target Audience
Healthcare practitioners who treat depression.
Upon completion of this online audioconference, the participant should be able to:
Identify several psychosocial comorbidities that frequently accompany clinical depression.
Describe various monotherapeutic or combination approaches to the treatment of depression with comorbid psychosocial disorders.
Define criteria by which a treated patient with depression is considered to be in remission.
Explain the impact of depression and anxiety disorders on quality of life and productivity.
Dr. Sheehan reports honoraria or consulting fees for lectures and presentations from Abbott Laboratories, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Boots Pharmaceuticals, Bristol-Myers Squibb, Burroughs-Wellcome, Charter Hospitals, Ciba-Eggy, Dista Products Company, Eli Lilly, Excerpta Medica Asia, Glaxo Pharmaceuticals, GlaxoSmithKline, Hospital Corporation of America, Humana, ICI, Kali-Duphar, Marion Merrill Dow, McNeil Pharmaceuticals, Mead Johnson, Merck Sharpe & Dohme, Organon, Novo Nordisk, Parke-Davis, Pfizer, Inc. Pharmacia & Upjohn, Rhone-Poulenc Rorer Pharmaceuticals, Roche Laboratories, Roerig, Sandoz Pharmaceuticals, Schering Corporation, SmithKine Beecham, Solvay Pharmaceuticals, TAP Pharmaceuticals, TGH-University Psychiatry Center, The Upjohn Company, Warner Chilcott, Wyeth-Ayerst Laboratories. Since 1973, Dr. Sheehan has received honoraria and travel expenses for lectures/presentations at meetings/symposia/education programs sponsored by the above organizations.
He is a stock shareholder in Layton Bioscience and Medical Outcome Systems.
He has received grant/research support from Abbott Laboratories, American Medical Association, Anclote Foundation, Bristol-Myers Squibb Pharmaceuticals Company, Burroughs-Wellcome Pharmaceutical Company, Eisai America, Inc., Forest Laboratories, Glaxo-Wellcome, International Clinical Research (ICR), Janssen Pharmaceutica Products, Kali Duphar Laboratories, Inc., Eli Lilly & Company, Mead Johnson, Merck Sharpe &Dohme, Ltd, National Institute of Drug Abuse, National Institutes of Health, Novartis Pharmaceuticals Corporation, Parke-Davis, Pfizer, Quintiles, Sandoz Pharmaceuticals Corporation, Sanofi-Synthelabo Recherche (LERS), SmithKline Beecham Pharmaceuticals, Tampa General Hospital-University Psychiatry Center, TAP Pharmaceuticals, The Upjohn Company, Warner Chilcott Pharmaceutical Company, Worldwide Clinical Trials, Wyeth-Ayerst Pharmaceutical Company, Zeneca Pharmaceuticals.
He has served or is serving as a consultant for: Faxmed Inc.(2001-present) o Cortex Pharmaceutical 2001-present o Parexel International Corporation (2001-present) o Pharmacia (2001-present) o GlaxoSmithKline (2001-present) o Sanofi-Synthelabo Research (2000-present) o AstraZeneca (2000-present) o Orion Pharma (2000-present) o Shire Laboratories, Inc.(1999) o World Health Organization (1998) o Forest Laboratories - NJ (1998) o Pierre Fabre, France (1998) o Lundbeck, Denmark (1998) o Alza Pharmaceuticals, Palo Alto, California (1998) o Layton Bioscience, California (1998) o Wyeth-Ayerst (1997-present) o Organon, Inc.(1997-1998) o Bristol--Myers Squibb (1996) o Pharmacia &&Upjohn (1996-1997) o Pfizer, Inc.(1996-1997)o National Anxiety Foundation (1992-present) o SmithKine Beecham Pharmaceuticals (1991-present) o Philadelphia College of Pharmacy & Science (1991-1992) o Abbott Laboratories (1991-1992) o Lilly Research Laboratories (1991) o Connecticut & Ohio Academies of Family Physicians (1990)o CPC Coliseum Medical Center (1989) o USF Friends of Research in Psychiatry, Board of Trustees (1989-present) o National Anxiety Awareness Program (1988) o Anxiety Disorders Resource Center (1987-1989) o APA Task Force on Treatments of Psychiatric Disorders (1987-1989) o APA Task Force on Benzodiazepine Dependency (1986-1989) o The Upjohn Company (1983-1986) o National Depressive & Manic Depressive Association (1986-1992) o Council on Anxiety Disorders (1986-1989) o Division of Drugs & Technology, American Medical Association (1985) o Ad Hoc Committee, Treatment Drug &Assessment Research Review Committee (RRC)of NIMH on Anxiety and Phobic Disorder Projects (1984) o American Psychiatric Association Working Group to revise DSM-III Anxiety Disorders Section (1984-1985) o US Congress - House of Representatives Committee (1985) o Anxiety Drug Efficacy Case, US Food & Drug Administration (1982) Credit Statements
Healthcare practitioners who participated in the live audioconference are not eligible to receive continuing education credit through the online version of this program.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education(ACCME) through the joint sponsorship of the
Dannemiller Memorial Educational Foundation and Medical Communications Media, Inc. The Dannemiller Memorial Educational Foundation is accredited by the ACCME to provide continuing medical education for physicians.
The Dannemiller Memorial Educational Foundation designates this educational activity for a maximum of 1 hour in category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the activity.
AKH Consultant is approved as a provider of pharmacy continuing education by the American Council of Pharmaceutical Education. AKH Consultant has designated this activity for 1.0 hours of continuing education credit. UPN#:077-999-02-003-H01.
AKH Consultant is approved as a provider of continuing nursing continuing education: AL #ABN0229; CA #CEP12070; DE #101; FL: #2851; IA #277; KS #LT0146-0338; NV #NV010495-3; and WV #WV97-0127.RN. This course is designed to meet the criteria for all state boards of nursing requiring continuing education.
Commercial Support Statements
This program is supported by an unrestricted educational grant from GlaxoSmithKline.
Click on the “start program” icon.
The next screen will permit you to check for or download RealAudio’s RealPlayer required to run this program. You will also find buttons that will permit you to start the program presentation, access other program elements, and take the post-test.
Clicking on “start the program” on this screen will begin the program presentation, which will take approximately 1 hour to complete.
You must be registered with cmecorner.com in order to complete the post-test. When you click on the post-test button, you will be brought to a screen that will confirm your registration status and provide an opportunity to register if you haven’t done so previously.
Instructions for completing and submitting the post-test are provided on the post-test screen.
A minimum score of 70% on the post-test is required for a CME or CE certificate.
The information contained in this program does not necessarily reflect the opinions or recommendations of the Dannemiller Memorial Educational Foundation, AKH Consultant, GlaxoSmithKline, or Medical Communications Media, Inc. Diagnostic procedures or treatments discussed in the program should not be utilized by clinicians without evaluation of patients’ conditions and possible contraindications or risks, and without a review of applicable manufacturer’s product information and comparison with recommendations of other authorities.